HIGHLIGHTS
- who: Experimental Hematology and colleagues from the DepartmentUniversity Medical, The Hague, The Netherlands have published the research work: Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study, in the Journal: (JOURNAL) of 10/06/2020
- what: The authors aimed to validate the prognostic ability of known (proteomic) markers measured pretreatment and to search for new proteomic markers that might be related to treatment response in CLL. The AUC of the model was higher (0.61) compared with that of the model including only . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.